Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2018 1
2019 2
2020 2
2021 2
2022 1
2023 1
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial.
Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Kimbung Mbandi S, Borate B, Mendelsohn SC, Hadley K, Hikuam C, Kaskar M, Musvosvi M, Bilek N, Self S, Sumner T, White RG, Erasmus M, Jaxa L, Raphela R, Innes C, Brumskine W, Hiemstra A, Malherbe ST, Hassan-Moosa R, Tameris M, Walzl G, Naidoo K, Churchyard G, Hatherill M; CORTIS-01 Study Team. Scriba TJ, et al. Lancet Infect Dis. 2021 Mar;21(3):354-365. doi: 10.1016/S1473-3099(20)30914-2. Epub 2021 Jan 25. Lancet Infect Dis. 2021. PMID: 33508224 Free PMC article. Clinical Trial.
BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection.
Schmidt AC, Fairlie L, Hellström E, Luabeya Kany Kany A, Middelkoop K, Naidoo K, Nair G, Gela A, Nemes E, Scriba TJ, Cinar A, Frahm N, Mogg R, Kaufman D, Dunne MW, Hatherill M; BCG REVAX Study Team. Schmidt AC, et al. N Engl J Med. 2025 May 8;392(18):1789-1800. doi: 10.1056/NEJMoa2412381. N Engl J Med. 2025. PMID: 40334156 Free PMC article. Clinical Trial.
A streamlined base editor engineering strategy to reduce bystander editing.
Valdez I, O'Connor I, Patel D, Gierer K, Harrington J, Ellis E, Caponetti SA, Sebra RP, Valley HC, Coote K, Mense M, Marro SG, Jiang T. Valdez I, et al. Among authors: valley hc. Nat Commun. 2025 Aug 30;16(1):8115. doi: 10.1038/s41467-025-63609-6. Nat Commun. 2025. PMID: 40885742 Free PMC article.
Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic setting.
Tameris M, Rozot V, Imbratta C, Geldenhuys H, Mendelsohn SC, Kany Luabeya AK, Shenje J, Tredoux N, Fisher M, Mulenga H, Bilek N, Young C, Veldsman A, Botes N, Thole J, Fritzell B, Mukherjee R, Jelsbak IM, Rodriguez E, Puentes E, Doce J, Marinova D, Gonzalo-Asensio J, Aguilo N, Martin C, Scriba TJ, Hatherill M; MTBVAC 202 study team. Tameris M, et al. EBioMedicine. 2025 Apr;114:105628. doi: 10.1016/j.ebiom.2025.105628. Epub 2025 Mar 17. EBioMedicine. 2025. PMID: 40101388 Free PMC article. Clinical Trial.
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial.
Borges ÁH, Russell M, Tait D, Scriba TJ, Nemes E, Skallerup P, van Brakel E, Cabibbe AM, Cirillo DM, Leuvennink-Steyn M, Rutkowski KT, Wood GK, Thierry-Carstensen B, Tingskov PN, Meldgaard EC, Kristiansen MP, Søndergaard RE, Hansen CH, Follmann F, Jensen CG, Gela A, Ntinginya NE, Ruhwald M, Shenje J, White L, Innes C, Selepe P, Ngaraguza B, Holmgren C, Collings T, Andersen P, Dawson R, Churchyard G, Sabi I, Diacon AH, Mortensen R, Hatherill M; POR TB study group. Borges ÁH, et al. Lancet Infect Dis. 2025 Jul;25(7):751-763. doi: 10.1016/S1473-3099(24)00814-4. Epub 2025 Mar 5. Lancet Infect Dis. 2025. PMID: 40056922 Clinical Trial.
A multimodal iPSC platform for cystic fibrosis drug testing.
Berical A, Lee RE, Lu J, Beermann ML, Le Suer JA, Mithal A, Thomas D, Ranallo N, Peasley M, Stuffer A, Bukis K, Seymour R, Harrington J, Coote K, Valley H, Hurley K, McNally P, Mostoslavsky G, Mahoney J, Randell SH, Hawkins FJ. Berical A, et al. Among authors: valley h. Nat Commun. 2022 Jul 29;13(1):4270. doi: 10.1038/s41467-022-31854-8. Nat Commun. 2022. PMID: 35906215 Free PMC article.
RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response.
Penn-Nicholson A, Mbandi SK, Thompson E, Mendelsohn SC, Suliman S, Chegou NN, Malherbe ST, Darboe F, Erasmus M, Hanekom WA, Bilek N, Fisher M, Kaufmann SHE, Winter J, Murphy M, Wood R, Morrow C, Van Rhijn I, Moody B, Murray M, Andrade BB, Sterling TR, Sutherland J, Naidoo K, Padayatchi N, Walzl G, Hatherill M, Zak D, Scriba TJ; Adolescent Cohort Study team; GC6-74 Consortium; SATVI Clinical and Laboratory Team; ScreenTB Consortium; AE-TBC Consortium; RePORT Brazil Team; Peruvian Household Contacts Cohort Team; CAPRISA IMPRESS team. Penn-Nicholson A, et al. Sci Rep. 2020 May 25;10(1):8629. doi: 10.1038/s41598-020-65043-8. Sci Rep. 2020. PMID: 32451443 Free PMC article.
14 results